top of page
Embryonic Stem Cells

NYU CAR-T AND PERSONALIZED IMMUNOTHERAPY LAB

Aiming to develop curative immunotherapies for all cancer patients

MISSION

Immunotherapies have revolutionized the treatment of cancer, resulting in cures in subsets of cancer patients, yet remain ineffective for the majority of patients. We aim to expand the use of curative immunotherapies to all cancer patients (pediatric and adult). Our work aims to address the major bottlenecks preventing wider use of immunotherapies by applying first principles: discovering tumor-specific targets using multi-omics approaches and engineering target-specific immune receptors using combined computational and experimental techniques. We develop and employ technologies at the intersection of genomics, proteomics, immunology, antibody engineering and computational biology.  We are generating a pipeline of new therapies for cancer patients in need as well as technologies to enable personalized immunotherapies. Resulting from these approaches, our novel class of peptide-centric (PC)-CAR T cells potently eradicate tumors in preclinical models and are entering clinical trials in 2023.

Established January 2023: 
Now Hiring

02_Deerfield_345PAS_01-Hero_031120.jpeg

Location

The Yarmarkovich lab will be housed in the brand new state-of-the-art facilities at the CURE building located in the heart of Manhattan.

Image by Florian Wehde

“Do not go where the path may lead, go instead where there is no path and leave a trail.”

-Ralph Waldo Emerson

GET IN TOUCH

PI: Mark Yarmarkovich, PhD

bottom of page